Center for Health Research, Kaiser Permanente Northwest, Portland, OR, USA.
BMC Infect Dis. 2011 Jul 15;11:194. doi: 10.1186/1471-2334-11-194.
Clostridium difficile is the most common cause of nosocomial infectious diarrhea in the United States. However, recent reports have documented that C. difficile infections (CDIs) are occurring among patients without traditional risk factors. The purpose of this study was to examine the epidemiology of CA-CDI, by estimating the incidence of CA-CDI and HA-CDI, identifying patient-related risk factors for CA-CDI, and describing adverse health outcomes of CA-CDI.
We conducted a population-based, retrospective, nested, case-control study within the University of Iowa Wellmark Data Repository from January 2004 to December 2007. We identified persons with CDI, determined whether infection was community-associated (CA) or hospital-acquired (HA), and calculated incidence rates. We collected demographic, clinical, and pharmacologic information for CA-CDI cases and controls (i.e., persons without CDI). We used conditional logistic regression to estimate the odds ratios (ORs) for potential risk factors for CA-CDI.
The incidence rates for CA-CDI and HA-CDI were 11.16 and 12.1 cases per 100,000 person-years, respectively. CA-CDI cases were more likely than controls to receive antimicrobials (adjusted OR, 6.09 [95% CI 4.59-8.08]) and gastric acid suppressants (adjusted OR, 2.30 [95% CI 1.56-3.39]) in the 180 days before diagnosis. Controlling for other covariates, increased risk for CA-CDI was associated with use of beta-lactam/beta-lactamase inhibitors, cephalosporins, clindamycin, fluoroquinolones, macrolides, and penicillins. However, 27% of CA-CDI cases did not receive antimicrobials in the 180 days before their diagnoses, and 17% did not have any traditional risk factors for CDI.
Our study documented that the epidemiology of CDI is changing, with CA-CDI occurring in populations not traditionally considered "high-risk" for the disease. Clinicians should consider this diagnosis and obtain appropriate diagnostic testing for outpatients with persistent or severe diarrhea who have even remote antimicrobial exposure.
艰难梭菌是美国最常见的医院感染性腹泻的病原体。然而,最近的报告记录表明艰难梭菌感染(CDI)也发生在没有传统危险因素的患者中。本研究的目的是通过估计社区获得性 CDI(CA-CDI)和医院获得性 CDI(HA-CDI)的发病率,确定与患者相关的 CA-CDI 危险因素,并描述 CA-CDI 的不良健康后果,来研究 CA-CDI 的流行病学。
我们在 2004 年 1 月至 2007 年 12 月期间,在爱荷华大学 Wellmark 数据资源库中进行了一项基于人群的回顾性巢式病例对照研究。我们确定了艰难梭菌感染患者,确定感染是社区获得性(CA)还是医院获得性(HA),并计算了发病率。我们收集了 CA-CDI 病例和对照(即没有 CDI 的人)的人口统计学、临床和药物信息。我们使用条件逻辑回归来估计 CA-CDI 的潜在危险因素的比值比(OR)。
CA-CDI 和 HA-CDI 的发病率分别为每 100,000 人年 11.16 和 12.1 例。与对照相比,CA-CDI 病例在诊断前 180 天内更有可能接受抗生素(调整后的 OR,6.09 [95%CI 4.59-8.08])和胃酸抑制剂(调整后的 OR,2.30 [95%CI 1.56-3.39])。在控制其他协变量后,使用β-内酰胺/β-内酰胺酶抑制剂、头孢菌素、克林霉素、氟喹诺酮类、大环内酯类和青霉素与 CA-CDI 的风险增加相关。然而,27%的 CA-CDI 病例在诊断前 180 天内未接受抗生素治疗,17%的病例没有任何 CDI 的传统危险因素。
我们的研究表明,CDI 的流行病学正在发生变化,CA-CDI 发生在传统上不被认为是该疾病“高危”的人群中。临床医生应考虑这一诊断,并为有持续性或严重腹泻且有抗生素暴露史的门诊患者进行适当的诊断性检测。